bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-1-121-131bloodjour-522Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSПрименение брентуксимаба ведотина для лечения ребенка, больного лимфоматоидным папулезомThe experience with Brentuximab vedotin in the treatment of lymphomatoid papulosis in a pediatric patienthttps://orcid.org/0000-0003-1709-0498ВолковаА. С.VolkovaA. S.

Волкова Анастасия Сергеевна, детский онколог отделения детской онкологии и гематологии (химиотерапии гемобластозов) № 1 НИИ детской онкологии и гематологии

115522, Москва

Anastasiya S. Volkova, Pediatric Oncologist of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) № 1 of the Research Institute of Pediatric Oncology and Hematology

115478, Moscow

anastasia.sergeevna.volkova@gmail.comhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Валиев Тимур Теймуразович, доктор медицинских наук, заведующий отделением детской онкологии и гематологии (химиотерапии гемобластозов) № 1 НИИ детской онкологии и гематологии

115522, Москва

119991, Москва

Timur T. Valiev, Dr. Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) № 1 of the Research Institute of Pediatric Oncology and Hematology

115478, Moscow

119991, Moscow

timurvaliev@mail.ruhttps://orcid.org/0000-0002-1082-8659КовригинаА. М.KovriginaA. M.

Ковригина Алла Михайловна, доктор биологических наук, заведующая патологоанатомическим отделением

125167, Москва

Alla M. Kovrigina, Dr. Sci. (Biol.), Head of the Pathology Department

125167, Moscow

   

kovrigina.a@blood.ruhttps://orcid.org/0000-0001-5911-553XБелышеваТ. С.BelyshevaT. S.

Белышева Татьяна Сергеевна, доктор медицинских наук, ведущий научный сотрудник научно-консультативного отделения НИИ детской онкологии и гематологии

115522, Москва

Tatyana S. Belysheva, Dr. Sci. (Med.), Leading Researcher of the Scientific Advisory Division

115478, Moscow

klinderma@mail.ruВарфоломееваС. Р.VarfolomeevaS. R.

Варфоломеева Светлана Рафаэлевна, доктор медицинских наук, профессор, директор НИИ детской онкологии и гематологии

115522, Москва

Svetlana R. Varfolomeeva, Dr. Sci. (Med.), Professor, Director of the Research Institute of Pediatric Oncology and Hematology

115478, Moscow

s.varfolomeeva@ronc.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской ФедерацииРоссияN.N. Blokhin National Medical Research Centre of OncologyRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияN.N. Blokhin National Medical Research Centre of Oncology; Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202419032024691121131Copyright © Волкова А.С., Валиев Т.Т., Ковригина А.М., Белышева Т.С., Варфоломеева С.Р., 20242024Волкова А.С., Валиев Т.Т., Ковригина А.М., Белышева Т.С., Варфоломеева С.Р.Volkova A.S., Valiev T.T., Kovrigina A.M., Belysheva T.S., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/522Введение

Введение. Лимфоматоидный папулез — это CD30-позитивное лимфопролиферативное заболевание, протекающее с первичным поражением кожи. Одной из терапевтических опций является применение анти-CD30 моноклонального антитела брентуксимаба ведотина.

Цель

Цель: представить клиническое наблюдение эффективного лечения лимфоматоидного папулеза брентуксимабом ведотином при рефрактерности заболевания к стандартным методам терапии у 6-летнего больного.

Основные сведения

Основные сведения. У больного К., 6 лет, после перенесенной острой респираторной вирусной инфекции отмечено появление высыпаний, расположенных преимущественно на коже конечностей, представленных единичными воспалительными папулами округлых очертаний, до 6–8 мм в диаметре, плотноватой консистенции при пальпации, с гладкой поверхностью и точечной зоной некроза белого цвета в центре отдельных элементов. Выполнена биопсия одного из элементов. По данным гистологического исследования установлен диагноз: «лимфоматоидный папулез, тип А». В связи с неэффективностью терапии топическими глюкокортикостероидными гормонами, пероральным приемом преднизолона, проведена эффективная терапия брентуксимабом ведотином.

Introduction

Introduction. Lymphomatoid papulosis is a CD30-positive lymphoproliferative disease with primary skin lesions. One of the therapeutic options is the use of anti-CD30 monoclonal antibody brentuximab vedotin.

Aim — to present the clinical observation of the effective treatment of lymphomatoid papulosis in a 6–year-old patient using brentuximab vedotin.

Main findings

Main findings. In patient K., 6 years old, after suffering from acute respiratory viral infection, the appearance of rashes was noted, located mainly on the skin of the extremities, represented by single infl ammatory papules of round shape, up to 6–8 mm in diameter, dense consistency upon palpation, with a smooth surface and a pinpoint area of white necrosis in the center of individual elements. A biopsy of one of the elements was performed. According to histological examination, a diagnosis was established: lymphomatoid papulosis, type A. Due to the ineffectiveness of therapy using topical glucocorticosteroids, oral administration of prednisolone, the patient was treated with brentuximab vedotin. A partial complete response was achieved.

   

лимфоматоидный папулездиагностикалечениебрентуксимаб ведотинlymphomatoid papulosisdiagnosistreatmentbrentuximab vedotinReferencesMacaulay W.L. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol. 1968; 97(1): 23–30. DOI: 10.1001/archderm.97.1.23.Macaulay W.L. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol. 1968; 97(1): 23–30. DOI: 10.1001/archderm.97.1.23.Willemze R., Meyer C.J., Van Vloten W.A., Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982; 107(2): 131– 44. DOI: 10.1111/j.1365-2133.1982.tb00331.x.Willemze R., Meyer C.J., Van Vloten W.A., Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982; 107(2): 131– 44. DOI: 10.1111/j.1365-2133.1982.tb00331.x.Martinez-Cabriales S.A., Walsh S., Sade S., Shear N.H. Lymphomatoid papulosis: an update and review. J Eur Acad Dermatol Venereol. 2020; 34(1): 59–73. DOI: 10.1111/jdv.15931.Martinez-Cabriales S.A., Walsh S., Sade S., Shear N.H. Lymphomatoid papulosis: an update and review. J Eur Acad Dermatol Venereol. 2020; 34(1): 59–73. DOI: 10.1111/jdv.15931.Schiemann W.P., Pfeifer W.M., Levi E., et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous Tcell lymphoma. Blood. 1999; 94: 2854–61.Schiemann W.P., Pfeifer W.M., Levi E., et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous Tcell lymphoma. Blood. 1999; 94: 2854–61.Haro R., Juarez A., Diaz J.L., et al. Regional lymphomatoid papulosis of the breast restricted to an area of prior radiotherapy. Cutis. 2016; 97: E15–9.Haro R., Juarez A., Diaz J.L., et al. Regional lymphomatoid papulosis of the breast restricted to an area of prior radiotherapy. Cutis. 2016; 97: E15–9.Matoula T., Nikolaou V., Marinos L., et al. Lymphomatoid papulosis type D in a fi ngolimod-treated multiple sclerosis patient. Mult Scler. 2016; 22: 1630–1.Matoula T., Nikolaou V., Marinos L., et al. Lymphomatoid papulosis type D in a fi ngolimod-treated multiple sclerosis patient. Mult Scler. 2016; 22: 1630–1.Park J.H., Lee J., Lee J.H., et al. Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis. Dermatology. 2012; 225: 259–63.Park J.H., Lee J., Lee J.H., et al. Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis. Dermatology. 2012; 225: 259–63.Outlaw W., Fleischer A., Bloomfeld R. Lymphomatoid papulosis in a patient with Crohn’s disease treated with infl iximab. Infl amm Bowel Dis. 2009; 15: 965–6.Outlaw W., Fleischer A., Bloomfeld R. Lymphomatoid papulosis in a patient with Crohn’s disease treated with infl iximab. Infl amm Bowel Dis. 2009; 15: 965–6.Leo A.M., Ermolovich T. Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol. 2009; 61: 540–1.Leo A.M., Ermolovich T. Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol. 2009; 61: 540–1.Garcia-Martinez P., Sitjas D., Llistosella E., et al. Imatinib treatment of lymphomatoid papulosis associated with myeloproliferative. Acta Derm Venereol. 2017; 97(7): 855–7. DOI: 10.2340/00015555-2669.Garcia-Martinez P., Sitjas D., Llistosella E., et al. Imatinib treatment of lymphomatoid papulosis associated with myeloproliferative. Acta Derm Venereol. 2017; 97(7): 855–7. DOI: 10.2340/00015555-2669.Mori M., Manuelli C., Pimpinelli N., et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood. 1999; 94(9): 3077–83.Mori M., Manuelli C., Pimpinelli N., et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood. 1999; 94(9): 3077–83.Toumi A., Fazal S., Litaiem N. Lymphomatoid Papulosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.Toumi A., Fazal S., Litaiem N. Lymphomatoid Papulosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.Uchiyama A., Motegi S., Ishikawa O. Angioinvasive lymphomatoid papulosis (type E): a fi rst Japanese case. Eur J Dermatol. 2016; 26: 507–8.Uchiyama A., Motegi S., Ishikawa O. Angioinvasive lymphomatoid papulosis (type E): a fi rst Japanese case. Eur J Dermatol. 2016; 26: 507–8.Nowicka D., Mertowska P., Mertowski S., et al. Etiopathogenesis, Diagnosis, and Treatment Strategies for Lymphomatoid Papulosis with Particular Emphasis on the Role of the Immune System. Cells. 2022; 11: 3697. DOI: 10.3390/cells11223697.Nowicka D., Mertowska P., Mertowski S., et al. Etiopathogenesis, Diagnosis, and Treatment Strategies for Lymphomatoid Papulosis with Particular Emphasis on the Role of the Immune System. Cells. 2022; 11: 3697. DOI: 10.3390/cells11223697.Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classifi cation of lymphoid neoplasms. Blood. 2016; 127(20): 2375–90. DOI: 10.1182/blood-2016-01-643569.Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classifi cation of lymphoid neoplasms. Blood. 2016; 127(20): 2375–90. DOI: 10.1182/blood-2016-01-643569.Wagner G., Rose C., Klapper W., Sachse M.M. Lymphomatoid papulosis. J Dtsch Dermatol Ges. 2020; 18(3): 199–205. DOI: 10.1111/ddg.14041.Wagner G., Rose C., Klapper W., Sachse M.M. Lymphomatoid papulosis. J Dtsch Dermatol Ges. 2020; 18(3): 199–205. DOI: 10.1111/ddg.14041.Kempf W., Kerl K., Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37(1): 24–9. DOI: 10.12788/j.sder.2018.001.Kempf W., Kerl K., Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37(1): 24–9. DOI: 10.12788/j.sder.2018.001.Mani V., George R., Vijayakumar K., Nair S. Type D lymphomatoid papulosis simulating aggressive epidermotropic cytotoxic lymphoma. Indian J Pathol Microbiol. 2016; 59(1): 81–3. DOI: 10.4103/0377-4929.174823.Mani V., George R., Vijayakumar K., Nair S. Type D lymphomatoid papulosis simulating aggressive epidermotropic cytotoxic lymphoma. Indian J Pathol Microbiol. 2016; 59(1): 81–3. DOI: 10.4103/0377-4929.174823.Валиев Т.Т., Ковригина А.М., Белышева Т.С. Клинические и иммуноморфологические особенности лимфоматоидного папулеза типа Е (обзор литературы и описание собственного клинического наблюдения). Клиническая онкогематология. 2020; 13(4): 389–94. DOI: 10.21320/2500-21392020-13-4-389-394.Valiev T.T., Kovrigina A.M., Belysheva T.S. Clinical and Immunomorphological Characteristics of Lymphomatoid Papulosis Type E (Literature Review and Case Report). Klinicheskaya onkogematologiya. 2020; 13(4): 389–94. (In Russian). DOI: 10.21320/2500-2139-2020-13-4-389-394.Karai L.J., Kadin M.E., Hsi E.D., et al. Chromosomal rearrangements of 6p25.3 defi ne a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013; 37(8): 1173–81. DOI: 10.1097/PAS.0b013e318282d01e.Karai L.J., Kadin M.E., Hsi E.D., et al. Chromosomal rearrangements of 6p25.3 defi ne a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013; 37(8): 1173–81. DOI: 10.1097/PAS.0b013e318282d01e.Pomsoong C., Suchonwanit P., Chanprapaph K., et al. Pityriasis Lichenoides Et Varioliformis Acuta and Lymphomatoid Papulosis Type F: A Case Report of Two Entities in One Patient. Clin Cosmet Investig Dermatol. 2022; 15: 1759–65. DOI: 10.2147/CCID.S379577.Pomsoong C., Suchonwanit P., Chanprapaph K., et al. Pityriasis Lichenoides Et Varioliformis Acuta and Lymphomatoid Papulosis Type F: A Case Report of Two Entities in One Patient. Clin Cosmet Investig Dermatol. 2022; 15: 1759–65. DOI: 10.2147/CCID.S379577.De Souza A., Camilleri M.J., Wada D.A., et al. Clinical histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009; 61: 993–1000.De Souza A., Camilleri M.J., Wada D.A., et al. Clinical histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009; 61: 993–1000.Bekkenk M.W., Geelen F.A., van Voorst Vader P.C., et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95: 3653–61.Bekkenk M.W., Geelen F.A., van Voorst Vader P.C., et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95: 3653–61.Partarrieu-Mejías F., García-Legaz-Martínez M., Martínez-Domenech Á., et al. Methotrexate-resistant acral lymphomatoid papulosis with complete remission after psoralen-ultraviolet A therapy. Dermatol Ther. 2020; 33(4): e13782. DOI: 10.1111/dth.13782.Partarrieu-Mejías F., García-Legaz-Martínez M., Martínez-Domenech Á., et al. Methotrexate-resistant acral lymphomatoid papulosis with complete remission after psoralen-ultraviolet A therapy. Dermatol Ther. 2020; 33(4): e13782. DOI: 10.1111/dth.13782.Kempf W., Pfaltz K., Vermeer M.H., et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118: 4024–35.Kempf W., Pfaltz K., Vermeer M.H., et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118: 4024–35.Everett M.A. Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol. 1984; 111(5): 631.Everett M.A. Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol. 1984; 111(5): 631.Vonderheid E.C., Sajjadian A., Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30- positive lymphoproliferative disorders. J Am Acad Dermatol. 1996; 34: 470–81.Vonderheid E.C., Sajjadian A., Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30- positive lymphoproliferative disorders. J Am Acad Dermatol. 1996; 34: 470–81.Bruijn M.S., Horváth B., van Voorst Vader P.C., et al. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2015; 173(5): 1319–22. DOI: 10.1111/bjd.13920.Bruijn M.S., Horváth B., van Voorst Vader P.C., et al. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2015; 173(5): 1319–22. DOI: 10.1111/bjd.13920.Fernández-de-Misa R., Hernández-Machín B., Servitje O., et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol. 2018; 43(2): 137–43. DOI: 10.1111/ced.13256.Fernández-de-Misa R., Hernández-Machín B., Servitje O., et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol. 2018; 43(2): 137–43. DOI: 10.1111/ced.13256.Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.Strathie Page S.J., Tait C.P. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol. 2015; 56(1): 77–83. DOI: 10.1111/ajd.12259.Strathie Page S.J., Tait C.P. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol. 2015; 56(1): 77–83. DOI: 10.1111/ajd.12259.AbuHilal M., Walsh S., Shear N. Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. J Cutan Med Surg. 2017; 21(6): 507–12. DOI: 10.1177/1203475417716366.AbuHilal M., Walsh S., Shear N. Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. J Cutan Med Surg. 2017; 21(6): 507–12. DOI: 10.1177/1203475417716366.Champagne T., Walsh S. Mycophenolic acid for lymphomatoid papulosis. J Cutan Med Surg. 2013; 17(5): 332–4. DOI: 10.2310/7750.2013.12111.Champagne T., Walsh S. Mycophenolic acid for lymphomatoid papulosis. J Cutan Med Surg. 2013; 17(5): 332–4. DOI: 10.2310/7750.2013.12111.van de Donk N.W., Dhimolea E. Brentuximab vedotin. MAbs. 2012; 4(4): 458–65. DOI: 10.4161/mabs.20230.van de Donk N.W., Dhimolea E. Brentuximab vedotin. MAbs. 2012; 4(4): 458–65. DOI: 10.4161/mabs.20230.Lewis D.J., Talpur R., Huen A.O., et al. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol. 2017 Dec 1; 153(12): 1302–6. DOI: 10.1001/jamadermatol.2017.3593.Lewis D.J., Talpur R., Huen A.O., et al. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol. 2017 Dec 1; 153(12): 1302–6. DOI: 10.1001/jamadermatol.2017.3593.Горенкова Л.Г., Кравченко С.К., Белоусова И.Э. Возможности брентуксимаб ведотина в лечении рецидивирующих/рефрактерных форм кожных Т-клеточных лимфом: обзор литературы и собственные наблюдения. Вестник дерматологии и венерологии. 2019; 95(2): 42–9. DOI: 10.25208/00424609-2019-95-2-42-49.Gorenkova L. G., Kravchenko S. K., Belousova I. E. Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation. Vestnik Dermatologii i Venerologii. 2019; 95(2): 42–9. (In Russian) DOI: 10.25208/0042-46092019-95-2-42-49.Torres-Navarro I., Navarro-Mira M.Á., de Unamuno-Bustos B., Botella-Estrada R. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. J Dtsch Dermatol Ges. 2020; 18(4): 378–80. DOI: 10.1111/ddg.14064.Torres-Navarro I., Navarro-Mira M.Á., de Unamuno-Bustos B., Botella-Estrada R. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. J Dtsch Dermatol Ges. 2020; 18(4): 378–80. DOI: 10.1111/ddg.14064.Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood. 2005; 105(10): 3768–85.Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood. 2005; 105(10): 3768–85.Miquel J, Fraitag S, Hamel-Teillac D., et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol. 2014; 171(5): 1138–46. DOI: 10.1111/bjd.13061.Miquel J, Fraitag S, Hamel-Teillac D., et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol. 2014; 171(5): 1138–46. DOI: 10.1111/bjd.13061.Nijsten T., Curiel-Lewandrowski C., Kadin M.E. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004; 140(3): 306–12. DOI: 10.1001/archderm.140.3.306.Nijsten T., Curiel-Lewandrowski C., Kadin M.E. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004; 140(3): 306–12. DOI: 10.1001/archderm.140.3.306.Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19): 1812–21. DOI: 10.1056/NEJMoa1002965.Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19): 1812–21. DOI: 10.1056/NEJMoa1002965.Duvic M., Tetzlaff M.T., Gangar P., et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32): 3759–65. DOI: 10.1200/JCO.2014.60.3787.Duvic M., Tetzlaff M.T., Gangar P., et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32): 3759–65. DOI: 10.1200/JCO.2014.60.3787.Mascolo A., Scavone C., Bertini M., et al. Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. Front Pharmacol. 2020; 11: 621Mascolo A., Scavone C., Bertini M., et al. Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. Front Pharmacol. 2020; 11: 621

The authors declare that there are no conflicts of interest present.